静脉格列本脲在药物与血管内治疗的大核心卒中:CHARM 随机临床试验亚组分析
该研究为 CHARM 试验的事后分析,纳入 147 例年龄≤70 岁、基线核心梗死体积<125 ml 的大半球梗死患者。结果显示静脉格列本脲组 90 天改良 Rankin 量表有有利偏移(校正共同比值比 2.11,95%CI 1.10-4.01,p=0.02);在接受血管内取栓的患者中获益更明显。作者认为结果为假设生成性证据,需前瞻性随机试验验证。
要点
- 静脉格列本脲与<125 ml大核心卒中90天功能结局有利偏移相关。
- 接受血管内取栓者中格列本脲组去骨瓣减压更少、中线移位更轻、死亡率更低。
- 该事后分析结果需前瞻性随机临床试验确认。
核心结论
- CHARM 试验事后分析提示,静脉格列本脲可能改善核心梗死体积<125 ml 的大核心卒中患者结局,尤其在血管内取栓治疗患者中。
- 结果为假设生成性证据,需前瞻性随机临床试验确认。
研究设计与样本
- CHARM 随机临床试验的事后分析,纳入年龄≤70 岁且基线核心梗死体积<125 ml 的大半球梗死患者,共 147 例。
- 基线平均年龄 58 岁,女性占 37%,基线 NIHSS 为 18,研究药物给药时间为 9.1±2.1 小时。
主要发现
- 静脉格列本脲组相对安慰剂组 90 天改良 Rankin 量表有有利偏移,校正共同比值比 2.11(95%CI 1.10-4.01,p=0.02)。
- 接受血管内取栓患者中,格列本脲组有利结局校正共同比值比 8.19(95%CI 1.60-42.0,p=0.01)。
- 接受血管内取栓患者中,格列本脲组去骨瓣减压术比例 0% 对 25%(P=0.02),中线移位 4.2±2.5 mm 对 7.6±5.5 mm(p=0.02),90 天死亡率 5.6% 对 31%(p=0.05)。
关键数值与推荐
- 纳入标准:年龄≤70 岁,CT 灌注或弥散磁共振测得缺血核心体积<125 ml。
- 主要终点:90 天改良 Rankin 量表偏移分析。
- 校正变量包括年龄、性别、基线 NIHSS、世界区域、组织型纤溶酶原激活剂和血管内取栓。
临床怎么用
- 该事后分析提示静脉格列本脲可能用于核心梗死体积<125 ml 的大核心卒中患者,尤其接受血管内取栓者。
- 当前证据为假设生成性,临床应用需等待前瞻性随机试验验证,不应据此改变常规实践。
局限性
- 本研究为 CHARM 试验的事后亚组分析,样本量有限(147 例),结果需前瞻性随机试验确认。
- 分析仅纳入年龄≤70 岁且核心梗死体积<125 ml 的患者,结论不能外推至其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Glibenclamide for Large Hemispheric Infarction Analyzing mRS and Mortality (CHARM) trial enrolled participants with large hemispheric infarction, randomized to a placebo or intravenous glyburide. Our objective in this post-hoc study was to evaluate the relationship between baseline stroke volume and the potential efficacy of i.v. glyburide. METHODS: Participants enrolled in CHARM and aged ≤70 years were included if a <125 ml ischemic core lesion volume was measured by computed tomography perfusion or diffusion magnetic resonance imaging. The primary endpoint was a shift analysis on the 90-day modified Rankin Scale. Independent variables included age, sex, baseline National Institutes of Health Stroke Scale, world region, tissue plasminogen activator, and endovascular thrombectomy. RESULTS: A total of 147 participants with a baseline large-core stroke volume <125 ml were available for this analysis (mean age 58 years, 37% women, baseline National Institutes of Health Stroke Scale 18, and the time to study drug was 9.1 ± 2.1 h). The median baseline core volume of 92 mL (IQR 81-107 ml) did not differ by treatment arm. The i.v. glyburide-treated participants had a favorable shift in outcome relative to the placebo (adjusted common odds ratio 2.11, 95% CI 1.10-4.01, p = 0.02). In patients who underwent endovascular thrombectomy, i.v. glyburide-treated subjects had a favorable outcome (adjusted common odds ratio 8.19, 95% CI 1.60-42.0, p = 0.01), fewer decompressive craniectomies (0% vs 25%, P = 0.02), less midline shift (4.2 ± 2.5 mm vs 7.6 ± 5.5 mm, p = 0.02), and lower 90-day mortality (5.6% vs 31%, p = 0.05) compared with the placebo, respectively. INTERPRETATION: This post-hoc analysis of the CHARM trial provides hypothesis-generating evidence that i.v. glyburide may improve outcome in large-core stroke <125 ml, especially among endovascular thrombectomy-treated patients. These results require confirmation in a prospective randomized clinical trial. ANN NEUROL 2025;98:616-624.
引用
- Kimberly WT, Saver JL, Campbell BCV, et al. Intravenous Glyburide in Medical and Endovascular-Treated Large-Core Stroke: A Subgroup Analysis of the CHARM Randomized Clinical Trial. Ann Neurol. 2025. PMID: 40476628. doi:10.1002/ana.27268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。